Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Sagent Pharmaceuticals Announces FDA Approval of Metoprolol Tartrate Injection, USP

By Pharmaceutical Processing | April 21, 2010

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced FDA approval of metoprolol tartrate injection, USP (metoprolol). The AP-rated product will be sold in latex-free 5 mg per 5 mL vials that feature Sagent’s proprietary PreventIV Measures(TM) labeling and packaging. Metoprolol is commonly used in the treatment of acute myocardial infarction (AMI). According to the American Heart Association, an estimated 1.4 million people annually will suffer a heart attack or AMI. IMS data indicates 2009 sales of metoprolol approximated $13 million. Sagent expects to launch the product shortly.

“Metoprolol is the third product approved this month and an important addition to our vital cardiovascular care portfolio, which already includes adenosine pre-filled syringes and vials, amiodarone pre-filled syringes, and labetalol vials,” said Jeffrey M. Yordon, Sagent’s chief executive officer, founder, and chairman of the board. “Our collaboration with Strides continues to be an enormous success, with metoprolol marking the sixth product approved under our joint venture.”

Under this venture, Sagent and Strides Arcolab are jointly developing, supplying and marketing more than 25 injectable products for the U.S. market. Strides is responsible for developing and manufacturing injectable products that Sagent will market in the United States.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE